Onkologische Welt 2019; 10(02): 60-61
DOI: 10.1055/a-0864-1337
Kongressnachlese
© Georg Thieme Verlag KG Stuttgart · New York

ASCO-GI 2019: Pankreaskarzinom

Stellschrauben in der Behandlung des Pankreaskarzinoms
Ine Schmale
1   Westerburg
› Author Affiliations
Further Information

Publication History

Publication Date:
24 May 2019 (online)

Während bei vielen Tumorentitäten große Fortschritte in der Behandlung zu berichten sind, bleibt das Pankreaskarzinom ein Tumor mit einer schlechten Prognose und wenigen Therapieoptionen. Beim Gastrointestinal Cancers Symposium (ASCO­GI) wurde eine Sitzung der frühen Detektion, der Sequenztherapie resektabler Tumoren und den Therapien der Zukunft beim Pankreaskarzinom gewidmet.

 
  • Literatur

  • 1 Sadot E. et al. Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms: An opportunity for identification of high-risk disease.. Ann Surg 2015; 262: 1102-1107.
  • 2 Al Efishat M. et al. Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas.. Ann Surg 2018; 268: 340-347.
  • 3 Al Efishat M. et al. Progression patterns in the remnant pancreas after resection of non-invasive or micro-invasive intraductal papillary mucinous neoplasms (IPMN).. Ann Surg Oncol 2018; 25: 1752-1759.
  • 4 Ryan DP. et al. Pancreatic adenocarcinoma.. N Engl J Med 2014; 371: 1039-1049.
  • 5 Ghaneh P. et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma.. Ann Surg 2019; 269: 520-529
  • 6 Jang JY. et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabin versus upfront surgery in patients with borderline resectabie pancreatic cancer: A prospective, randomized, open-label, multicenter phase ⅔ trial.. Ann Surg 2018; 268: 215-222
  • 7 Van Tienhoven. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.. ASCO 2018, Abstract LBA4002
  • 8 Murphy JE. et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial.. JAMA Oncol 2018; 4: 963-969
  • 9 O’Reilly EM. et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.. Cancer 2018; 124: 1374-1382